risks of taking glp 1 Key Takeaways Patients GLP-1 receptor agonists for weight loss had a 41% lower risk obesity-associated cancers compared with patients prescribed diet or exercise. Patients taking tirzepatide had substantially greater cancer GLP-1 receptor agonists are increasingly

The literature identifies hypoglycemia as the most significant documented risk, driven by IGF-1 LR3s effect on cellular glucose uptake, alongside receptor desensitization with prolonged exposure and contraindications for individuals with a history of malignancy

Its tempting because you might still lose weight, but it can result in developing bad habits that are hard to kick once you reach your healthy weight and look to wean off the drug

GLP-1 (glucagon-like peptide-1) is a hormone your gut produces naturally after you eat

Oct 1992;16(4):960-967

Swelling is a double-edged sword in the intestine

Protopapas N, Hamilton LE, Warkentin R et al (2019) The perforatorium and postacrosomal sheath of rat spermatozoa share common developmental origins and protein constituents